Gut microbiota dysbiosis

Gut microbiota dysbiosis refers to an **imbalance** in the composition and/or function of the microorganisms residing within the gastrointestinal tract. This state is characterized by either an overgrowth of potentially harmful microbes (“pathobionts”)—such as *Clostridioides difficile*, *Enterococcus faecalis*, *Campylobacter*—or a loss/reduction in beneficial commensal species like *Bifidobacterium* and *Lactobacillus*. Dysbiosis can result from factors including dietary changes, antibiotics use, infections, stress, environmental exposures, or underlying diseases. It has been implicated as both a marker and potential contributor to various conditions ranging from inflammatory bowel diseases and metabolic disorders to neurodegenerative diseases. While not itself a molecular target but rather a pathological state/condition reflecting altered ecosystem dynamics within the gut,[1][3] therapeutic strategies aim at restoring eubiosis using probiotics/prebiotics/FMT among others.[2][4] The field continues to evolve with ongoing research into precise diagnostic markers and optimal intervention strategies.\n\n**Note:** \"Gut microbiota dysbiosis\" is not itself a molecule/receptor/enzyme but describes an altered ecological state; thus it does not fit standard definitions for canonical drug targets such as receptors or enzymes.[1][5]

Other names

Gut dysbiosisMicrobiome imbalanceIntestinal dysbiosisDysbiosis of gut microbiota

Drugs and interventions act by restoring microbial balance through one or more mechanisms such as:\n - Replenishing beneficial bacteria populations with probiotics/prebiotics/FMT[4][6]\n - Reducing pathogenic/pathobiont bacteria via competitive exclusion or direct inhibition\n - Modulating production of metabolites like short-chain fatty acids that influence host immunity and inflammation[2][6]